CN106994141B - 一种治疗便秘的中药组合物及其制备方法 - Google Patents
一种治疗便秘的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN106994141B CN106994141B CN201610048579.8A CN201610048579A CN106994141B CN 106994141 B CN106994141 B CN 106994141B CN 201610048579 A CN201610048579 A CN 201610048579A CN 106994141 B CN106994141 B CN 106994141B
- Authority
- CN
- China
- Prior art keywords
- parts
- constipation
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 235000006533 astragalus Nutrition 0.000 claims abstract description 24
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 23
- 241000005787 Cistanche Species 0.000 claims abstract description 22
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 21
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 19
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 19
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 17
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 14
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 9
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 8
- 244000088415 Raphanus sativus Species 0.000 claims abstract description 5
- 210000003813 thumb Anatomy 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 93
- 241000218236 Cannabis Species 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 239000003921 oil Substances 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- 210000000582 semen Anatomy 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 241000229143 Hippophae Species 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 235000003935 Hippophae Nutrition 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000020374 simple syrup Nutrition 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 210000000952 spleen Anatomy 0.000 abstract description 20
- 240000000950 Hippophae rhamnoides Species 0.000 abstract description 15
- 210000003734 kidney Anatomy 0.000 abstract description 10
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 240000004308 marijuana Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 16
- 241000125175 Angelica Species 0.000 description 14
- 235000001287 Guettarda speciosa Nutrition 0.000 description 14
- 241001061264 Astragalus Species 0.000 description 11
- 241000220259 Raphanus Species 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 210000004233 talus Anatomy 0.000 description 11
- 230000013872 defecation Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000976 ink Substances 0.000 description 9
- 238000007873 sieving Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000002040 relaxant effect Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- -1 compound diphenoxylate Chemical class 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 229960004192 diphenoxylate Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000336291 Cistanche deserticola Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 241000336316 Cistanche tubulosa Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 235000019057 Raphanus caudatus Nutrition 0.000 description 2
- 235000011380 Raphanus sativus Nutrition 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 241000336315 Cistanche salsa Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000735234 Ligustrum Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000308150 Orobanchaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010038080 Rectal ulcer Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗便秘的中药组合物及其制备方法。该中药组合物的有效组分由以下重量份数的药材制成:沙棘叶5‑40份、肉苁蓉2‑20份、火麻仁2‑20份、黄芪2‑30份、女贞子2‑20份、当归5‑20份、枳椇子3‑10份、莱菔子(炒)1‑10份。该中药组合物具有补脾益肾、增强免疫力、润肠通便的作用,且安全无毒副作用。
Description
技术领域
本发明属于中药领域。更具体地,涉及一种治疗便秘的中药组合物及其制备方法。
背景技术
便秘是大便秘结的简称,粪便在肠道内滞留时间过久,排便时间延长,每周排便少于3次者称为便秘。便秘是临床上常见的一个症状,虽不是大病,但对人体的危害很大,甚至可以致命的。便秘对消化系统的影响是最为常见的,便秘可以导致腹胀、腹痛、排气多、食欲不振、消化不良、直肠溃疡等等,可增加肠癌的发病率;此外,便秘可引发自身中毒,造成精神和内分泌紊乱,引发面部灰暗、痤疮、头痛、心烦、失眠、脾气暴躁等,大便干结引起排便困难,造成腹腔压力升高,血压升高,诱发心绞痛、心律失常、心梗、脑梗等。此外,严重便秘还可造成急性肠壁坏死、破裂、穿孔、扭转,严重时也会致人死命。所以,便秘是健康的大敌。
一般认为,便秘是由于年龄的增长,人体进食量和体力活动减少,使得胃肠道分泌减少,结肠的张力与蠕动减弱和肛垫区的直肠肛管移行,上皮敏感程度下降等综合原因造成的。中医理论认为便秘的发生主要源于体内津液不充分,肠道失其濡养,因而结滞。金元时期著名医家李东垣在《脾胃论·脾胃胜衰论》谓:“夫脾胃不足,皆为血病。是阳气不足,阴气有余,故九窍不通,诸阳气根于阴血中,阴血受火邪则阴盛,阴盛则上乘阳分,而阳道不行,无生发升腾之气也。”火伏于血中,耗散真阴,津液亏少,造成津液不能濡润而成大便秘结。由于津血同源,脾胃损伤运化失调,后天之本泛源,血分枯涩,肠道失其润泽,则大便秘结。李东垣治疗便秘基本是立足于脾胃虚弱,血分涩滞为主,以养、升、润为主,常能取得满意的疗效。
目前,随着居民饮食结构、精神和社会因素等多方面影响,便秘患病率呈逐渐上升趋势。从全球看,发达国家便秘的发病率普遍高于发展中国家。目前文献所报道我国成人普通人群便秘的患病率为3.19%-11.6%,其中功能性便秘的发病率为6%。女性发病率明显高于男性。成年便秘人群有相当部分是因为脾胃虚弱,不能运化五谷杂粮从而大便秘结。特别是老年人作为便秘的高发人群,总发病率已达到11.5%,且随着年龄的增长,发病率不断升高。中医认为老年人便秘多因为气血阴阳虚衰,脏腑机能衰退,脾胃虚弱,气血虚少,气虚则大肠传送无力。血虚则肠道失润,阴津不足,则津亏肠燥,阳虚而阴寒内盛,糟粕固涩,不得下行,故而发生便秘。
便秘的治疗方法主要包括调整饮食、运动疗法、排便指导、心理调护、药物治疗及手术治疗等。其中,前4种方法属于基础治疗,需要长期坚持。而手术治疗的无效率和复发率较高,仅能短时间缓解症状,费用较高,得不到患者的认同。所以药物治疗是目前使用最为频繁的方法,但是药物治疗基本以泻药为主,虽然见效快,但副反应多,长期用药易产生药物依赖性,只能短期使用缓解症状,如年老体衰者和脾胃虚弱的患者用这类药物,实际上是加重了患者的病情,因此,开发一种安全有效的健康产品非常必要。
发明内容
本发明的第一个目的是提供一种治疗便秘的中药组合物,通过选择合适的药食同源原料及其配比,达到补脾益肾、增强免疫力、润肠通便的显著作用,且安全无毒副作用。
本发明的第二个目的是提供一种治疗便秘的中药组合物的制备方法。
本发明的第三个目的是提供一种治疗便秘的药物,其包括本发明所述的中药组合物。
为达到上述目的,本发明采用下述技术方案:
本发明提供一种用于便秘的中药组合物,其有效组分由以下重量份数的药材制成:沙棘叶5-40份、肉苁蓉2-20份、火麻仁2-20份、黄芪2-30份、女贞子2-20份、当归5-20份、枳椇子3-10份、莱菔子(炒)1-10份。
进一步地,其有效组分还可以由以下重量份数的药材制成:沙棘叶5-30份、肉苁蓉2-18份、火麻仁2-15份、黄芪2-20份、女贞子2-15份、当归5-15份、枳椇子5-8份、莱菔子(炒)1-8份。
沙棘叶:为胡颓子科沙棘属植物沙棘(Hippophae rhamnoides L.)的干燥叶。性味酸、涩、温,归脾、胃、肺、心经。具有健脾消食,止咳化痰,活血散瘀的作用,可用于脾虚食少,食积腹痛,咳嗽痰多,胸痹心痛,瘀血经闭,跌仆瘀肿。沙棘叶所含黄酮类成分为主要活性成分,其中以槲皮素、异鼠李素、山柰酚及其苷类芦丁等成分为主。具有抗心肌缺血、抗心律失常、提高耐缺氧能力、降低血清胆固醇、抑制血小板聚集以及抗溃疡、抗肿瘤、抗炎、抗过敏、抗氧化、抗衰老、抗辐射和抗菌、抗病毒等广泛的药理作用。据报道,沙棘叶总黄酮含量明显高于沙棘其他药用部位。
肉苁蓉:为列当科植物肉苁蓉(Cistanche deserticola Y.C.Ma)或管花肉苁蓉(Cistanche tubulosa(Schenk)Wight)的肉质茎。性味甘、咸、温。归肾,大肠经。具有补肾阳、益精血、润肠通便的作用。用于肾阳不足,精血亏虚,阳痿不孕,腰膝酸软,筋骨无力,肠燥便秘。
火麻仁:为桑科植物大麻(Cannabis sativa L.)的干燥成熟果实。味甘性平,归脾、胃、大肠经,能润肠通便,兼有滋养补虚作用。适用于老人、产妇及体弱津血不足的肠燥便秘证。有文献(贺海波,石孟琼.火麻仁的化学成分和药理活性研究进展,中国民族民间医药,2010,15:56-57)显示:大麻酚类是火麻仁成瘾性和毒性成分,主要存在于叶、茎和根中,在果仁中含量很低,而且多存在于果皮中。为了减少本品的成瘾性,处方中优选去果皮的火麻仁。
黄芪:为豆科植物蒙古黄芪或膜荚黄芪的干燥根。性甘微温,归肺,脾经。具有补气升阳,固表止汗,利水消肿,生津养血,行滞通痹,脱毒排脓,敛疮生肌的作用。黄芪能促进机体代谢、抗疲劳、促进血清和肝脏蛋白质的更新;有明显的利尿作用,能消除实验性肾炎尿蛋白;能改善贫血动物现象;能升高低血糖,降低高血糖;能兴奋呼吸;能增强和调节机体免疫功能,对干扰素系统有促进作用,可提高机体的抗病力;黄芪能够延长小肠的峰电位发放时间,改善肠管平滑肌的血循环,促进小肠的兴奋和运动。
女贞子:为木犀科女贞属植物女贞(Ligustrum lucidum Ait.)的干燥果实。性甘,凉,味苦,归肝,肾经。具有滋补肝肾,明目乌发,强腰膝的作用。用于阴虚内热,头晕,目花,耳鸣,腰膝酸软,须发早白等。
当归:为形科植物当归(Angelica sinensis(Oliv.)Diels)的根。味甘性辛,温。归肝,心,脾经。具有补血活血,调经止痛,润肠通便的作用。用于血虚萎黄、眩晕心悸、月经不调、经闭痛经、虚寒腹痛、肠燥便秘、风湿痹痛、跌扑损伤、痈疽疮疡等。
枳椇子:为鼠李科植物枳椇的带有肉质果柄的果实。药用最早见于《唐本草》。李时珍《本草纲目》认为其"味甘、性平、无毒,有止渴除烦,去膈上热,润五脏,利大小便,功同蜂蜜",是糖尿病患者的理想果品。
莱菔子:为十字花科植物萝卜(Raphanus sativus L.)的干燥成熟种子。性辛味甘,平。归肺,脾,胃经。具有消食除胀,降气化痰作用。可用于饮食停滞,脘腹胀痛,大便秘结,积滞泻痢,痰壅喘咳等。本发明优选炒制的莱菔子,因莱菔子有“生升熟降”的特点,炒制后的莱菔子降气开郁而不伤阴,降气通便作用优于枳实厚朴。
本发明还提供了上述中药组合物的制备方法,该方法包括:
(1)取火麻仁、莱菔子(炒)粉碎,得粗粉混合物,用超临界CO2萃取得油,备用;
(2)取肉苁蓉、黄芪、当归、枳椇子、女贞子和沙棘叶,加6-10倍量的水浸泡至少1小时,然后密闭煎煮2-3次,每次0.5-2小时,合并煎液,加乙醇,使煎液中含醇量达到50%-70%,静置过夜,取上清液,浓缩至60℃条件下相对密度1.0-1.2,干燥得提取物,备用;
(3)取步骤(1)制得的油和步骤(2)制得的提取物混合,即得有效组分。
进一步地,上述方法中,所述干燥为喷雾干燥、减压干燥或流化床干燥。
本发明还提供了一种治疗便秘的药物,该药物包括上述中药组合物,进一步地,为了便于使用和携带,该药物还可以包括药剂学可接受的辅料,通过常规工艺制成各种剂型。
进一步地,所述药剂学可接受的辅料包括淀粉、微晶纤维素、蔗糖、糊精、乳糖、葡萄糖、氯化钠、羧甲基纤维素钠、交联聚乙烯吡咯烷酮、硬脂酸镁、微粉硅胶、维生素C、柠檬酸和亚硫酸钠、木糖醇、聚乙二醇、单糖浆、磷酸氢钙、二氧化硅、乙醇、苯甲酸钠、吐温80中的一种或几种。
在本发明中,所述治疗便秘的药物的剂型优选为口服制剂,包括但不限于片剂、胶囊剂、颗粒剂、丸剂、糖浆剂或口服液。
本发明的有益效果如下:
本发明中药物组合物及其制剂有明显的通便作用,且安全无毒副作用。本品攻补兼施,以养、润为主,方中沙棘叶、肉苁蓉协同作用滋补脾肾,火麻仁润肠通便,黄芪、女贞子、当归和枳椇子协同作用补气滋阴,补血润肠,莱菔子下气除胀,共凑补肾健脾,缓下通便的作用。本方攻补兼施,标本兼治,对脾胃气虚或老年体弱患者尤为适用。本品选用药材均为药食同源材料,食用安全有效,有一定的预防作用,可长期服用。适于年老体衰、久病虚弱等脾肾虚弱的患者服用,在临床运用很有价值,值得临床推广应用。
具体实施方式
为了更清楚地说明本发明,下面结合优选实施例对本发明做进一步的说明。本领域技术人员应当理解,下面所具体描述的内容是说明性的而非限制性的,不应以此限制本发明的保护范围。
实施例1
沙棘叶20份、肉苁蓉15份、火麻仁10份、黄芪15份、女贞子10份、当归12份、枳椇子10份、莱菔子(炒)8份
制备方法如下:
1)取处方量火麻仁、莱菔子(炒)粉碎,过2号筛,得粗粉混合物,用超临界CO2萃取得油,备用;
2)取处方量肉苁蓉、黄芪、当归、枳椇子、女贞子、沙棘叶,加10倍量纯水浸泡1小时,然后密闭煎煮2次,每次1小时,合并煎液,加适量乙醇,使煎液中含醇量达到50%,静置过夜,取上清液,回收乙醇,浓缩至60℃条件下相对密度1.0-1.2,喷雾干燥得提取物,备用;
3)将上述第1)步工艺制得的油和经第2)步工艺制得的提取物粉混合,即得有效组分;再将该有效组分与适量微晶纤维素、乳糖、交联羧甲基纤维素纳混合均匀,加入润湿剂制备软材,制粒,干燥,整粒,填充胶囊,包装,即得胶囊剂。
实施例2
沙棘叶30份、肉苁蓉15份、火麻仁15份、黄芪30份、女贞子12份、当归15份、枳椇子10份、莱菔子(炒)8份
制备方法如下:
1)取处方量火麻仁、莱菔子(炒)粉碎,过2号筛,得粗粉混合物,用超临界CO2萃取得油,备用;
2)取处方量肉苁蓉、黄芪、当归、枳椇子、女贞子、沙棘叶,加8倍量纯水浸泡2小时,然后密闭煎煮2次,每次1小时,合并煎液,加适量乙醇,使煎液中含醇量达到70%,静置过夜,取上清液,回收乙醇,浓缩至60℃条件下相对密度1.0-1.2,减压干燥得提取物,备用;
3)将上述第1)步工艺制得的油和经第2)步工艺制得的提取物粉混合,即得有效组分;再将该有效组分与适量微晶纤维素、乳糖、交联羧甲基纤维素纳、磷酸氢钙、二氧化硅混合均匀,用干法制粒机制粒,颗粒过20目筛;
4)将制备的颗粒与交联羧甲基纤维素纳和硬脂酸镁混合均匀后,调节片重、硬度,压片,包装,即得片剂。
实施例3
沙棘叶10份、肉苁蓉10份、火麻仁8份、黄芪8份、女贞子5份、当归8份、枳椇子5份、莱菔子(炒)4份
制备方法如下:
1)取处方量火麻仁、莱菔子(炒)粉碎,过2号筛,得粗粉混合物,用超临界CO2萃取得油,备用;
2)取处方量肉苁蓉、黄芪、当归、枳椇子、女贞子、沙棘叶,加6倍量纯水浸泡1小时,然后密闭煎煮2次,每次1小时,合并煎液,加适量乙醇,使煎液中含醇量达到65%,静置过夜,取上清液,回收乙醇,浓缩至60℃条件下相对密度1.0-1.2,流化床干燥得提取物,备用;
3)将上述第1)步工艺制得的油和经第2)步工艺制得的提取物粉混合,即得有效组分;再将该有效组分与适量的蔗糖、糊精混合均匀,用水制备软材,制粒,干燥,整粒,分装后即得颗粒剂。
实施例4
沙棘叶15份、肉苁蓉10份、火麻仁10份、黄芪8份、女贞子6份、当归10份、枳椇子10份、莱菔子(炒)8份
制备方法如下:
1)取处方量火麻仁、莱菔子(炒)粉碎,过2号筛,得粗粉混合物,用超临界CO2萃取得油,备用;
2)取处方量肉苁蓉、黄芪、当归、枳椇子、女贞子、沙棘叶,加10倍量纯水浸泡1小时后,密闭煎煮2次,每次1小时,合并煎液,加适量乙醇,使煎液中含醇量达到65%,静置过夜,取上清液,回收乙醇,浓缩至60℃条件下相对密度1.0-1.2,喷雾干燥得提取物,备用;
3)将上述第1)步工艺制得的油与微晶纤维素(PH-102NF型号)、磷酸氢钙混合均匀后,加入二氧化硅、硬脂酸镁混匀,调节片重及压力,制备片剂1。
4)将上述第2)步制得的提取物与适量微晶纤维素、乳糖、交联羧甲基纤维素纳混合均匀,用干法制粒机制粒,颗粒过20目筛,将制备的颗粒和硬脂酸镁混合均匀后,调节片重、硬度,压片,即得片剂2。
5)将片剂1与片剂2装入00#胶囊,铝塑包装后即得胶囊剂。
实施例5
沙棘叶25份、肉苁蓉15份、火麻仁10份、黄芪20份、女贞子10份、当归10份、枳椇子10份、莱菔子(炒)8份
制法如下:
1)取处方量火麻仁、莱菔子(炒)粉碎,过2号筛,得粗粉混合物,用超临界CO2萃取得油,备用;
2)取处方量肉苁蓉、黄芪、当归、枳椇子、女贞子、沙棘叶,加10倍量纯水浸泡1小时,然后密闭煎煮2次,每次1小时,合并煎液,加适量乙醇,使煎液中含醇量达到50%,静置过夜,取上清液,回收乙醇,浓缩至60℃条件下相对密度1.0-1.2,喷雾干燥得提取物,备用;
3)用纯化水溶解黄原胶,溶解完全后加入吐温80摇匀作为乳化剂备用;
4)取适量纯化水及乙醇的混合物溶解步骤2)所得提取物,溶解完全后加入乳化剂搅匀,作为水相和乳化剂混合液备用;
5)匀速搅拌步骤4)所得混合液,取步骤1)所得油溶液缓缓加入混合液中,待全部加入油溶液后开启乳化机乳化,即得口服液。
实施例6
沙棘叶30份、肉苁蓉15份、火麻仁15份、黄芪20份、女贞子10份、当归8份、枳椇子8份、莱菔子(炒)8份
制法如下:
1)取处方量火麻仁、莱菔子(炒)粉碎,过2号筛,得粗粉混合物,用超临界CO2萃取得油,备用;
2)取处方量肉苁蓉、黄芪、当归、枳椇子、女贞子、沙棘叶,加10倍量纯水浸泡1小时,然后密闭煎煮2次,每次1小时,合并煎液,加适量乙醇,使煎液中含醇量达到50%,静置过夜,取上清液,回收乙醇,浓缩至60℃条件下相对密度1.0-1.2,喷雾干燥得提取物,备用;
3)取步骤1)所得的油溶液及步骤2)所得的提取物混合后加入适量5%羧甲基纤维素钠水溶液制备软材,加入挤出滚圆机制备母丸,将制得的母丸放入滚圆机中滚圆处理后即得丸剂。
实施例7
沙棘叶20份、肉苁蓉15份、火麻仁10份、黄芪15份、女贞子10份、当归8份、枳椇子8份、莱菔子(炒)8份
制法如下:
1)取处方量火麻仁、莱菔子(炒)粉碎,过2号筛,得粗粉混合物,用超临界CO2萃取得油,备用;
2)取处方量肉苁蓉、黄芪、当归、枳椇子、女贞子、沙棘叶,加10倍量纯水浸泡1小时,然后密闭煎煮2次,每次1小时,合并煎液,加适量乙醇,使煎液中含醇量达到50%,静置过夜,取上清液,回收乙醇,浓缩至60℃条件下相对密度1.0-1.2,喷雾干燥得提取物,备用;
3)取步骤2)所得提取物,加入适量纯化水溶解,待溶解完全后加入蔗糖至饱和,过滤后滤液备用;
4)取乙醇与步骤1)所得油溶液混合后加入步骤3)所得的滤液中,搅匀即得糖浆剂。
试验例1本发明药物治疗便秘临床观察
一般资料:本组患者80例(男45例,女35例,年龄40-81岁),随机分为实验组A、实验组B、实验组C、实验组D、对照组(服用福松),每组16人。
实验组A:服用实施例1所得通便制剂,一日2次,一次3粒;
实验组B:与实施例1组方不同之处在于,组方去掉肉苁蓉,沙棘叶的用量为35份,按照实施例1方法制得通便制剂,一日2次,一次3粒;
实验组C:与实施例1组方不同之处在于,组方去掉当归,黄芪的用量增为27份,按照实施例1方法制得通便制剂,一日2次,一次3粒;
实验组D:按照实施例1的组方配比一日用剂量,用常规煎煮法制备,步骤包括:先用水浸泡30分钟,然后武火煎开,改为文火煎30分钟;滤出药液,加水继续煎煮,第二遍煎煮用武火煎开后文火20分钟。两遍药液混合在一起,大约有两碗,分2次服用,一日服完。每日服用前煎煮一付;
对照组:福松(聚乙二醇4000散),日2次,每次10g;
5组患者的性别、年龄、病程、病情程度经X2检验,差异无统计学意义(P>0.05),具有可比性。
方法:观察每组对象口服各药后每天症状及变化。观察期半个月。
疗效判定:临床症状积分标准为(1)排便间隔时间:≤48h为0分,48~72h为2分,≥72h为4分,(2)排便时间:≤5min为0分,5~10min为2分,≥10min为4分(3)大便性状:成形不干结者为0分,大便干结者为2分,大便干结如羊粪者为4分,疗效判定标准为:痊愈:大便恢复正常,所有症状消失,积分降至0分。显效:大便正常或基本正常,排便间隔时间在48h内,其他症状基本消失,积分减少≥2/3。有效:大便干硬程度明显改善,排便间隔时间缩短24h,其他症状明显好转,积分减少在1/3~2/3之间。无效:大便情况无好转,排便间隔时间无改变,其他症状无改善,积分减少≤1/3。
临床结果见下表:
表1两组疗效比较
福松主要成分是聚乙二醇4000,属于渗透性泻药,具有润湿、软化大便,刺激结肠的作用,实验组A与对照组相比,痊愈率和总有效率明显高于对照组,且没有腹痛、泄泻的不良反应;与实验组B、C相比,疗效均优于B、C组,说明实验组A组方合理,各药材之间有协同作用;实验组A与实验组D相比,A组结果优于D组,说明将组方中油性部分单独提取,富集油性成分,有利于提高本品的疗效。
试验例2:本品对便秘小鼠小肠推动运动的影响
动物:选用健康昆明种小鼠,体重18-22g,共60只,雌雄各半(由北京维通利华实验动物公司提供);
试剂:复方地芬诺酯片(厂家、批号),活性炭,明胶。
实验组药物:
实验组A:按上述实施例3制备本发明药物制剂颗粒剂,按照7.45g生药/kg灌胃给药;
实验组B:与实施例3组方不同之处在于,组方去掉肉苁蓉,沙棘叶的用量为20份,按照实施例3方法制得通便制剂,按照7.45g生药/kg灌胃给药;
实验组C:与实施例3组方不同之处在于,组方去掉当归,黄芪的用量为16份,按照实施例3方法制得通便制剂,照7.45g生药/kg灌胃给药;
1)墨汁配制:准确称取明胶10g,于碾钵中碾细,加蒸馏水50ml,煮沸至溶液透明,加入准确称量的活性碳5g,再次煮沸,待溶液冷却后加入蒸馏水定容至100ml,用前摇匀。
2)0.25%复方地芬诺酯混悬浮液的配制:取复方地芬诺酷片25mg,用研钵研碎成粉末后加蒸馏水定容至100mL,临用前配制。
方法:
将小鼠60只适应性喂养7天后,随机分成5组,雌雄各半,每组12只。分别为空白对照组、模型组(复方地芬诺酯组),实验组A、实验组B、实验组C。采取灌胃法,空白对照组和模型组灌蒸馏水(0.4ml/只),药物组分别连续给予受试物14d后,各组小鼠禁食不禁水24h,称重,药物组给予受试物、对照组及模型组给予等量蒸馏水。30min后,除空白对照组外,其余各组灌胃复方地芬诺酯5mg/kg。30min后,各组灌胃墨汁0.4mL/只。经20min,脱颈椎处死动物,开腹取小肠,剪取上端自幽门,下端至回盲部的肠管,轻拉成直线,测量小肠全长和幽门至墨水运动前沿位移,计算小肠墨汁推进率。
表2对地芬诺酯引起的便秘模型小鼠小肠墨汁推进率的影响
与模型组相比,P<0.01
由上表可见,模型组小鼠的小肠墨汁推进率显著低于空白对照组,表明便秘模型建立成功。经统计分析,实验组A、B、C小鼠的墨汁推进率均高于模型组,表明具有促进小鼠小肠运动的作用。其中,实验组A的墨汁推进率远远高于实验组B和实验组C,说明实验组A的药物之间协同作用好于实验组B和实验组C。
显然,本发明的上述实施例仅仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定,对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动,这里无法对所有的实施方式予以穷举,凡是属于本发明的技术方案所引伸出的显而易见的变化或变动仍处于本发明的保护范围之列。
Claims (9)
1.一种治疗便秘的中药组合物,其特征在于,其有效组分由以下重量份数的药材制成:沙棘叶5-40份、肉苁蓉2-20份、火麻仁2-20份、黄芪2-30份、女贞子2-20份、当归5-20份、枳椇子3-10份、炒莱菔子1-10份;
且通过如下步骤制备:
(1)取火麻仁、炒莱菔子粉碎,得粗粉混合物,用超临界CO2萃取得油,备用;
(2)取肉苁蓉、黄芪、当归、枳椇子、女贞子和沙棘叶,加6-10倍量的水浸泡至少1小时,然后密闭煎煮2-3次,每次0.5-2小时,合并煎液,加乙醇,使煎液中含醇量达到50%-70%,静置过夜,取上清液,浓缩至60℃条件下相对密度1.0-1.2,干燥得提取物,备用;
(3)取步骤(1)制得的油和步骤(2)制得的提取物混合,即得有效组分。
2.根据权利要求1所述的中药组合物,其特征在于,其有效组分由以下重量份数的药材制成:沙棘叶5-30份、肉苁蓉2-18份、火麻仁2-15份、黄芪2-20份、女贞子2-15份、当归5-15份、枳椇子5-8份、炒莱菔子1-8份。
3.权利要求1或2所述的中药组合物的制备方法,其特征在于,包括如下步骤:
(1)取火麻仁、炒莱菔子粉碎,得粗粉混合物,用超临界CO2萃取得油,备用;
(2)取肉苁蓉、黄芪、当归、枳椇子、女贞子和沙棘叶,加6-10倍量的水浸泡至少1小时,然后密闭煎煮2-3次,每次0.5-2小时,合并煎液,加乙醇,使煎液中含醇量达到50%-70%,静置过夜,取上清液,浓缩至60℃条件下相对密度1.0-1.2,干燥得提取物,备用;
(3)取步骤(1)制得的油和步骤(2)制得的提取物混合,即得有效组分。
4.权利要求3所述的制备方法,其特征在于,步骤(2)中,所述干燥为喷雾干燥、减压干燥或流化床干燥。
5.一种治疗便秘的药物,其特征在于,所述药物包括权利要求1或2所述的中药组合物。
6.根据权利要求5所述的药物,其特征在于,所述药物还包括药剂学可接受的辅料。
7.根据权利要求6所述的药物,其特征在于,所述药剂学可接受的辅料包括淀粉、微晶纤维素、蔗糖、糊精、乳糖、葡萄糖、氯化钠、羧甲基纤维素钠、交联聚乙烯吡咯烷酮、硬脂酸镁、微粉硅胶、维生素C、柠檬酸和亚硫酸钠、木糖醇、聚乙二醇、单糖浆、磷酸氢钙、二氧化硅、乙醇、苯甲酸钠、吐温80中的一种或几种。
8.根据权利要求5所述的药物,其特征在于,所述药物的剂型为口服制剂。
9.根据权利要求8所述的药物,其特征在于,所述口服制剂为片剂、胶囊剂、颗粒剂、丸剂、糖浆剂或口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610048579.8A CN106994141B (zh) | 2016-01-25 | 2016-01-25 | 一种治疗便秘的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610048579.8A CN106994141B (zh) | 2016-01-25 | 2016-01-25 | 一种治疗便秘的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106994141A CN106994141A (zh) | 2017-08-01 |
CN106994141B true CN106994141B (zh) | 2020-08-14 |
Family
ID=59428226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610048579.8A Active CN106994141B (zh) | 2016-01-25 | 2016-01-25 | 一种治疗便秘的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106994141B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107897615A (zh) * | 2017-11-20 | 2018-04-13 | 宁国平衡健康管理有限公司 | 一种用于改善便秘的宣木瓜固体饮料 |
CN115944669B (zh) * | 2022-07-20 | 2024-01-30 | 中国人民解放军海军军医大学 | 一种缓解便秘的中药组合物及其制备方法和应用 |
CN116832084B (zh) * | 2023-07-31 | 2024-05-17 | 苏州市中医医院 | 一种治疗便秘的组合物及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101623364A (zh) * | 2009-04-17 | 2010-01-13 | 黑龙江北奇神药业有限责任公司 | 一种用于治疗便秘的药茶及其制法 |
CN101965884A (zh) * | 2010-09-17 | 2011-02-09 | 高原圣果沙棘制品有限公司 | 一种润肠通便袋泡茶剂的配方 |
-
2016
- 2016-01-25 CN CN201610048579.8A patent/CN106994141B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN106994141A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048933B (zh) | 一种治疗小儿腹泻的中药组合物及其制备方法 | |
CN101797326B (zh) | 一种治疗肠鸣腹泻的中药制剂及其制备方法 | |
CN102698137B (zh) | 一种具有降低血压作用的组合物及其制备方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN103690919B (zh) | 用于治疗仔猪缺铁性贫血的药物及其制备方法 | |
CN104873763A (zh) | 一种调理气虚体质的保健品 | |
CN105749179A (zh) | 治疗代谢综合征的中药组合物 | |
CN107362213B (zh) | 一种具有通便功能的组合物及其制备方法 | |
CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
CN105031517A (zh) | 一种降三高的铁皮石斛保健茶及其制备方法 | |
CN104958646A (zh) | 一种润肠通便的中药制剂及其制备方法 | |
CN106994141B (zh) | 一种治疗便秘的中药组合物及其制备方法 | |
CN102580048B (zh) | 减肥中药及制备方法 | |
CN102106965B (zh) | 一种治疗软组织急性损伤的组合物及其应用 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN105232987A (zh) | 一种促进神经外科术后康复的中药 | |
CN104623615A (zh) | 一种治疗哮喘的药物 | |
CN104840686A (zh) | 一种降压保健茶 | |
CN104815275A (zh) | 一种治疗妊娠反应的内服药物及其制备方法 | |
CN114712466B (zh) | 一种具有减肥养颜功效的药物及其制备方法 | |
CN101810751B (zh) | 一种治疗小儿肠系膜淋巴结发炎的中药制剂 | |
CN102218131A (zh) | 一种生肌接骨外用中草药组合物 | |
CN106902250A (zh) | 一种中西医联合治疗糖尿病的复方药物 | |
CN105214001B (zh) | 一种治疗高血压合并冠心病的中药组合物 | |
CN104758849A (zh) | 一种治疗绝经期骨质疏松症的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |